Toppublicaties

Melanoom

Geselecteerd door: Melanoom
  • november 2023

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

  • Kirkwood JM, Del Vecchio M, Weber J et al.
Duiding door Sofie Wilgenhof

Bempegaldesleukine en nivolumab geen effect op uitgezaaid melanoom
  • oktober 2023

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

  • Diab A, Gogas H, Sandhu S, et al.
  • augustus 2023

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

  • Ari VanderWalde, Shay L. Bellasea, Kari L. Kendra
  • juli 2023

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

  • Elisa A Rozeman, Judith M Versluis, Karolina Sikorska
  • juni 2023

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

  • Khattak A, Weber J S, Meniawy T, et al.

Pembrolizumab voor én na operatie geeft eventvrij overlevingsvoordeel melanoom
  • maart 2023

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

  • Patel S P, Othus M, Chen Y, et al.
  • januari 2023

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

  • Chesney J A, Ribas A, Long G V, et al.
  • november 2022

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

  • Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas
  • oktober 2022

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

  • Olivier J van Not, Rik J Verheijden, Alfonsus J M van den Eertwegh
  • oktober 2022

Neoadjuvant relatlimab and nivolumab in resectable melanoma

  • Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton
  • oktober 2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

  • Georgina V Long, Jason J Luke, Muhammad A Khattak
  • september 2022

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

  • Atkins MB, Lee SJ, Chmielowski B, et al.
Gedownload van https://medischeoncologie.nl/ op 18-04-2024 om 22:29. Copyright (C) 2024 BPM Medica.

Deel deze pagina